Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris A Karlovich

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer Journal (Sudbury, Mass.)|July 24, 2019
Clinical Applications of Next-Generation Sequencing in Precision OncologyChris A Karlovich, P Mickey Williams
Trends in Genetics : TIG|June 5, 2002
Genotype to phenotype: associations, errors and complexityLaura C Lazzeroni, Chris A Karlovich
Clinical Lung Cancer|October 4, 2018
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorElena Helman, Minh Nguyen, Chris A Karlovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Nature Communications|November 15, 2016
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer Journal (Sudbury, Mass.)|July 24, 2019
Clinical Applications of Next-Generation Sequencing in Precision OncologyChris A Karlovich, P Mickey Williams
Trends in Genetics : TIG|June 5, 2002
Genotype to phenotype: associations, errors and complexityLaura C Lazzeroni, Chris A Karlovich
Clinical Lung Cancer|October 4, 2018
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorElena Helman, Minh Nguyen, Chris A Karlovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Nature Communications|November 15, 2016
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Pageof 1